McMaster TOGETHER Trial: Ivermectin a No Show While Fluvoxamine Shows Some Promise

McMaster TOGETHER Trial: Ivermectin a No Show While Fluvoxamine Shows Some Promise

Recently, McMaster University's Professor Ed Mills, principal investigator of the Together trial, highlighted interim analysis results evidencing no impact of ivermectin and some other repurposed study drugs while pointing to some promise for Fluvoxamine. TOGETHER is a randomized, Adaptive Platform trial investigating several possible treatments, including ivermectin. After many therapies disappointed, Fluvoxamine, an SSRI commonly used for depression, showed some promise as a repurposed treatment. The study isn't completed, as there is still a 28-day monitoring period, but Mills recently presented the findings, which are already making the news rounds. While a disappointment for those tracking Ivermectin studies, those critical of the study raise legitimate points for consideration.

Dr. Ed Mills presented the study results during an August 6 event sponsored by the National Institutes of Health. Mills led this study that looked into several treatments, from hydroxychloroquine and lopinavir to ivermectin and Fluvoxamine. The trial was led by McMaster University, engaging with trial sites in Brazil. He was supported by Kristian Thorlung from McMaster University and Cyte...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee